Mitokinin
Mitokinin is a discovery-stage biotechnology company developing PINK1 targeted therapeutics for the treatment of neurodegenerative and mitochondrial diseases. Mitokinin's lead program targets idiopathic Parkinson's disease. Investors include Mission BioCapital, Pfizer Ventures, and Samambaia Investments.
Last updated on
About Mitokinin
Estimated Revenue
$1M-$10MEmployees
1-10Funding / Mkt. Cap
$5MCategory
Industry
BiotechnologyLocation
City
San FranciscoState
CaliforniaCountry
United StatesMitokinin
Find your buyer within Mitokinin
Tech Stack (9)
